Education
About Us
Working with TipRanks
Follow Us
Glaukos (GKOS)
NYSE:GKOS
GKOS Stock Chart & Stats
$96.49
$1.50(0.96%)
At close: 4:00 PM EST
$96.49
$1.50(0.96%)
Day’s Range― - ―
52-Week Range$73.16 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)1.42M
Market Cap
$5.08B
Enterprise Value$4.51B
Total Cash (Recent Filing)$273.71M
Total Debt (Recent Filing)$104.31M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Feb 19, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding57,434,740
10 Day Avg. Volume1,211,908
30 Day Avg. Volume1,421,171
Financial Highlights & Ratios
PEG Ratio150.23
Price to Book (P/B)10.31
Price to Sales (P/S)20.63
P/FCF Ratio-116.98
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue9.60
Enterprise Value/Gross Profit12.49
Enterprise Value/Ebitda-116.09
Forecast
1Y Price Target
$117.30Price Target Upside21.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-0.82
Revenue Forecast (FY)$493.74M
Bulls Say, Bears Say
Bulls Say
Earnings PerformanceThird-quarter sales were 9% above the Street, driven largely by a $6 million iDose beat where Glaukos continues to see strength in both the number of accounts and utilization within existing accounts.
Growth ProspectsEpioxa is seen as a compelling growth driver besides iDose, with an attractive WAC of roughly $78,500 and an estimated 10,000 patients annually treated.
Market OpportunityKeratoconus impacts about 600,000 people annually, representing a significant market opportunity for GKOS estimated at approximately $3 billion.
Bears Say
Growth LimitationsThe MACs targeting iDose is concerning for Glaukos Corp due to its importance in the company's long-term growth trajectory.
Market DisruptionGlaukos continues to expect material disruption in the fourth quarter as patients delay Photrexa procedures for the recently approved Epioxa procedure set to launch.
Regulatory ChallengesThe upcoming CAC meeting to discuss drug-eluting systems suggests potential challenges ahead, similar to past issues faced with MIGS devices.
Glaukos News
GKOS FAQ
What was Glaukos’s price range in the past 12 months?
Glaukos lowest stock price was $73.16 and its highest was $163.71 in the past 12 months.
What is Glaukos’s market cap?
Glaukos’s market cap is $5.08B.
When is Glaukos’s upcoming earnings report date?
Glaukos’s upcoming earnings report date is Feb 19, 2026 which is in 91 days.
How were Glaukos’s earnings last quarter?
Glaukos released its earnings results on Oct 29, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.261 by $0.101.
Is Glaukos overvalued?
According to Wall Street analysts Glaukos’s price is currently Undervalued.
Does Glaukos pay dividends?
Glaukos does not currently pay dividends.
What is Glaukos’s EPS estimate?
Glaukos’s EPS estimate is -0.21.
How many shares outstanding does Glaukos have?
Glaukos has 57,434,740 shares outstanding.
What happened to Glaukos’s price movement after its last earnings report?
Glaukos reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.261. Following the earnings report the stock price went up 13.893%.
Which hedge fund is a major shareholder of Glaukos?
Currently, no hedge funds are holding shares in GKOS
Glaukos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.30 (21.57% Upside)
$117.30 (21.57% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 425.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.9%
Last 30 Days ▲ 40.4%
Last 30 Days ▲ 40.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.09%
12-Months-Change
Fundamentals
Return on Equity
-12.19%
Trailing 12-Months
Asset Growth
7.86%
Trailing 12-Months
Company Description
Glaukos
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
GKOS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Glaukos showcased strong financial performance with record sales and significant product approvals, particularly the FDA approval of Epioxa. However, the company faces challenges with transitioning its Corneal Health franchise and establishing market access for new products.View all GKOS earnings summariesGKOS Stock 12 Month Forecast
Average Price Target
$117.30
▲(21.57% Upside)
Technical Analysis
Integer Holdings
―
Ufp Technologies
―
Tandem Diabetes Care
―
LivaNova
―
Irhythm Technologies
―
Ownership Overview
3.71% Insiders
37.18% Mutual Funds
27.42% Other Institutional Investors
8.40% Public Companies and
Individual Investors